PTC Therapeutics | PTCT - Operating Profit


PTC Therapeutics reported $3.49M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Alnylam Pharmaceuticals USD -29.96M 13.76M Sep/2025
Amgen USD 3.96B 464M Dec/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Cytokinetics USD -166.76M 55.25M Sep/2025
Daiichi Sankyo JPY 89.54B 42.01B Dec/2025
Gilead Sciences USD 3.51B 810M Sep/2025
Incyte USD 431.31M 120.49M Sep/2025
Ionis Pharmaceuticals USD -160.18M 300.02M Sep/2025
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Roche Holding CHF 9.56B 3.8B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
TG Therapeutics USD 29.36M 5.48M Sep/2025
Ultragenyx Pharmaceutical USD -170.89M 22.68M Sep/2025
Vertex Pharmaceuticals USD 1.24B 84.6M Sep/2025
Xencor USD -47.52M 14.35M Sep/2025